OmicsBank has raised $2.25 million to expand access to overseas patient data for biopharma training and research. The funding reflects the expanding commercial value of health data pipelines for machine learning and AI-enabled discovery. The company’s pitch centers on making multinational datasets usable for training while meeting the operational needs of drug developers who increasingly seek coverage beyond domestic cohorts. For the sector, the round is a reminder that data infrastructure—licensing, governance and harmonization—can be as strategically important as lab tooling when it comes to building AI-ready discovery programs.